SAN DIEGO–(BUSINESS WIRE)–Vividion announces publication of first peer-reviewed clinical data from Phase 1 study of VVD-214, investigational oral inhibitor of WRN.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
